Insomnia Market is Projected to Boom by 2036 Owing to the Launch of Novel Therapies | DelveInsight

The market dynamics for Insomnia is witnessing steady growth driven by the rising Disease Prevalence and Diagnosis Rates, Increasing Demand for Effective Pharmacological Therapies, and Growing Preference for Personalized and Non-pharmacological Treatment Approaches. Additionally, the launch of emerging therapies such as Seltorexant (Johnson & Johnson), HETLIOZ (Vanda Pharmaceuticals), and others will further fuel the market.

DelveInsight, a leading market research firm, announces the release of its latest report, "DelveInsight's Insomnia Market Insights, Epidemiology, and Market Forecast 2036." This comprehensive report provides an in-depth understanding of Insomnia, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Insomnia Market
• The market size for Insomnia in the leading markets is expected to grow significantly by 2036.
• The United States accounted for the highest Insomnia treatment market size in 7MM in 2025, in comparison to the other major markets, i.e., EU4 countries, the United Kingdom, and Japan.
• DelveInsight's analysis indicates that the diagnosed prevalent cases of insomnia across the 7MM were approximately 90 million in 2025, highlighting the disorder's significant presence across different populations.
• Data indicates that approximately 60 million diagnosed prevalent cases of insomnia were reported in the United States in 2025, while the cases are expected to increase during the forecast period.
• Secondary research indicates that the prevalence of insomnia in females was approximately 58% compared to 42% in males in the United States in 2025.
• Leading insomnia companies, such as Johnson & Johnson, Vanda Pharmaceuticals, and others, are developing new insomnia treatment drugs that can be available in the insomnia market in the coming years.
• The promising insomnia therapies in clinical trials include Seltorexant (JNJ-42847922), HETLIOZ (tasimelteon), and others.

Keen to know more about the market? Request our sample page at https://www.delveinsight.com/sample-request/insomnia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr

Key Factors Driving the Insomnia Market
• Rising Disease Prevalence and Diagnosis Rates: Increasing awareness of sleep disorders, improved screening tools, and expanding healthcare access are helping identify more patients with insomnia. Earlier diagnosis and better recognition of insomnia conditions are contributing to treatment demand.
• Increasing Demand for Effective Pharmacological Therapies: The pharmacological treatment of insomnia primarily involves orexin receptor antagonists such as suvorexant, lemborexant, and daridorexant, along with benzodiazepines, non-benzodiazepines, and melatonin receptor agonists. Newer-generation therapies with improved safety profiles are also gaining traction.
• Growing Preference for Personalized and Non-drug Therapies: Psychotherapies such as Cognitive Behavioral Therapy for Insomnia (CBT-I) are increasingly utilized. Behavioral therapies and sleep-focused interventions are also gaining traction.

Insomnia Competitive Landscape
• Several insomnia drugs in development include Seltorexant (Johnson & Johnson), HETLIOZ (Vanda Pharmaceuticals).
• These candidates target diverse mechanisms such as orexin receptor antagonism (Seltorexant), circadian rhythm modulation (HETLIOZ), aiming to improve sleep initiation and maintenance with better efficacy and fewer side effects than current treatments.

Discover more about therapies set to grab major Insomnia market share at: https://www.delveinsight.com/sample-request/insomnia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr

Recent Developments in the Insomnia Market
• In January 2026, Johnson & Johnson reported that topline results from ongoing clinical trials evaluating Seltorexant for insomnia are expected during the forecast period.
• In January 2026, ongoing studies evaluating Seltorexant in patients with sleep disorders are underway to assess its therapeutic potential.
• In January 2025, Vanda Pharmaceuticals reported continued development of HETLIOZ (tasimelteon) for insomnia treatment.
• In October 2024, emerging collaborations and research initiatives have supported the development of novel insomnia therapies targeting sleep regulation pathways.

What is Insomnia?
Insomnia, also known as a sleep disorder, causes difficulty in initiating sleep, maintaining sleep, or early morning awakenings that significantly impact daily functioning. These fluctuations go beyond typical sleep disturbances, leading to impaired cognitive and physical performance that disrupt a person's ability to manage everyday tasks. Symptoms range from difficulty sleeping to chronic sleep deprivation. Daytime fatigue and impaired functioning may appear, heightening misdiagnosis risks. Long-term complications remain a major concern, necessitating tailored treatment.

Insomnia Epidemiology Segmentation
The Insomnia epidemiology section provides insights into the historical and current Insomnia patient pool and forecasted trends for the leading markets. The Insomnia market report proffers epidemiological analysis for the study period 2022-2036 in the leading markets, segmented into:
• Total Diagnosed Prevalent Cases of Insomnia
• Type-specific Diagnosed Prevalent Cases of Insomnia
• Severity-specific Diagnosed Prevalent Cases of Insomnia
• Age-specific Diagnosed Prevalent Cases of Insomnia

Scope of the Insomnia Market Report
• Therapeutic Assessment: Insomnia current marketed and emerging therapies
• Insomnia Market Dynamics: Key Market Forecast Assumptions of Emerging Insomnia Drugs and Market Outlook
• Key Companies: Johnson & Johnson, Vanda Pharmaceuticals, and others
• Key Therapies: Seltorexant (JNJ-42847922), HETLIOZ (tasimelteon), DAYVIGO, QUVIVIQ, BELSOMRA, and others
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Insomnia Market Access and Reimbursement

To know more about Insomnia companies working in the treatment market, visit https://www.delveinsight.com/sample-request/insomnia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents
1. Insomnia Market Report Introduction
2. Executive Summary for Insomnia
3. SWOT Analysis of Insomnia
4. Insomnia Patient Share (%) Overview at a Glance
5. Insomnia Market Overview at a Glance
6. Insomnia Background and Overview
7. Insomnia Epidemiology and Patient Population
8. Country-Specific Patient Population of Insomnia
9. Insomnia Current Treatment and Medical Practices
10. Insomnia Unmet Needs
11. Insomnia Emerging Therapies
12. Insomnia Market Outlook
13. Country-Wise Insomnia Market Analysis (2022-2036)
14. Insomnia Market Access and Reimbursement of Therapies
15. Insomnia Market Drivers
16. Insomnia Market Barriers
17. Insomnia Appendix
18. Insomnia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.